Overview

Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults

Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to produce a new treatment that would benefit adult subjects by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance). This project is designed to study the innovative idea that oral immunotherapy (OIT), the ingestion of small increasing amounts of food allergen, will desensitize subjects with peanut hypersensitivity by regulating their mucosal and systemic immune reactivity and cause long-term tolerance.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill